hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06377462 id: VEXAS-Registry briefTitle: Multicenter, Interdisciplinary National VEXAS Registry With Accompanying Biomaterial Collection overallStatus: RECRUITING date: 2024-03-13 date: 2029-12-31 date: 2030-12-31 date: 2024-04-22 date: 2024-04-22 name: Technische Universität Dresden class: OTHER name: Bristol-Myers Squibb name: University Hospital Munich briefSummary: The aim is rapid collection of real-life data on the epidemiology, treatment and disease course in patients with VEXAS syndrome during routine clinical practice and collect biomaterials to evaluate genotype-phenotype associations, determine optimal treatment schedule, identify diagnostic features and biomarkers conditions: VEXAS Syndrome studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 500 type: ESTIMATED measure: Collection of epidemiological data on VEXAS measure: Collection and monitoring of initial disease manifestations measure: Documentation of the treatment approaches and therapy sequences measure: Analysis of clinical-relevant clinical endpoints measure: Describe disease cluster measure: Laboratory diagnostics measure: Correlation clinical endpoints with treatment approaches measure: Quality of life data (QoL), fatigue questionnaire (Facit-F) measure: Accompanying translational research measure: Collection of Biospecimens sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Universitätsklinikum Carl Gustav Carus status: RECRUITING city: Dresden zip: 01307 country: Germany name: Katja Sockel, Dr. med. role: CONTACT lat: 51.05089 lon: 13.73832 hasResults: False
nctId: NCT06377449 id: UIL-CSP-18052023 briefTitle: Influence of Lung Ultrasonography on the Prognosis and Postoperative Outcomes in Cardiac Surgical Patients overallStatus: NOT_YET_RECRUITING date: 2024-05-15 date: 2025-05-15 date: 2026-01-01 date: 2024-04-22 date: 2024-04-22 name: Saint Petersburg State University, Russia class: OTHER briefSummary: The goal of this interventional is to assess advantages of the ultrasound examination of the lungs in the early postoperative period in cardiac surgical patients after heart surgeries requiring cardiopulmonary bypass. Evaluation of pulmonary complications and outcomes during mid-term follow-up, as well as comparison of ultrasound examination and traditional roentgenologic methods (X-ray examination and CT of the chest) will be performed. The main question\[s\] it aims to answer are:
* Does early identification of interstitial pulmonary edema (based on number of visualised B-lines in the early postoperative period), influences mid-term outcomes in this cohort of patients Participants will undergo ultrasound examination of the lungs on postoperative day 1, 3, 5 and 7 after heart surgery. Based on ultrasound findings and degree of interstitial pulmonary edema, medical (diuretics, anti-inflammatory, e.t.c) therapy will be modified.
Researchers will compare this group of patients with control group, in which ultrasound examination will be performed in the same time frames, but no changes in medical management based on ultrasound findings will be made to see if timely administered medical therapy, based on ultrasound findings, can significantly improve symptoms, hospital lengths of stay and outcomes of this patients. conditions: Ischemic Heart Disease conditions: Aortic Stenosis, Severe conditions: Aortic Insufficiency conditions: Mitral Stenosis conditions: Mitral Insufficiency conditions: Mitral Stenosis With Insufficiency conditions: Tricuspid Insufficiency conditions: Ascending Aortic Aneurysm studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Prospective, randomized, single-center study with 2 groups of patients (investigating and control arms) primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 186 type: ESTIMATED name: Ultrasound examination of the lungs measure: The number of participants with interstitial pulmonary edema at the day of hospital discharge, according to ultrasound lung examination measure: Postoperative pulmonary complications measure: Cumulative dosage of diuretics measure: Number of nights at home after hospital discharge sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Saint Petersburg State University Clinic city: Saint Petersburg zip: 190020 country: Russian Federation name: Sergei M Efremov, MD, PhD role: CONTACT phone: +79137946090 email: sergefremov@mail.ru lat: 59.93863 lon: 30.31413 hasResults: False
nctId: NCT06377436 id: PRAISE briefTitle: Prevention of Disability in the Frail Elderly Person Through an Innovative Customised and Multidimensional Training Programme acronym: PRAISE overallStatus: RECRUITING date: 2023-03-20 date: 2024-12-31 date: 2024-12-31 date: 2024-04-22 date: 2024-04-22 name: University of Milan class: OTHER briefSummary: The goal of this clinical trial is to implement a personalized training program to prevent functional decline in frail subjects but not yet disable. The purpose of the project is to test the training in a subject at particularly high risk of entering the disabled condition. A total of 80 frail subjects, divide the participants into two groups "Divida Senso Group" (experimental group) and "Standard of care Group" (Control group) will be recruited.
The expected outcome is to slow down a functional decline not only in isolation in the domains trained by the program. conditions: Frailty studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 80 type: ESTIMATED name: Experimental training measure: Changes in the Functional decline measure: Intrinsic Capacity (IC) measure: Intreaction between IC and cardiac autonomic control (CAC) sex: ALL minimumAge: 65 Years stdAges: OLDER_ADULT facility: Gabriella CERRI status: RECRUITING city: Milano zip: 20100 country: Italy name: Gabriella GC CERRI, Full Professor role: CONTACT phone: +393402527675 email: gabriella.cerri@unimi.it lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06377423 id: A54678775 briefTitle: Comparison Between Direct Composite and Indirect Ceramic Laminate Veneers in Multiple Diastema Closure Cases overallStatus: COMPLETED date: 2021-08-01 date: 2024-01-01 date: 2024-01-10 date: 2024-04-22 date: 2024-04-22 name: Prince Sattam Bin Abdulaziz University class: OTHER briefSummary: Thus, the present study aimed to evaluate the longevity of direct composite compared to indirect ceramic laminate veneers in multiple diastema closure cases using USPHS criteria. The formulated null hypothesis was that there is no significant difference in the clinical performance of direct composite and indirect ceramic laminate veneers in multiple diastema closure cases over two years. conditions: Dental Leakage studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 28 type: ACTUAL name: Direct technique name: Indirect technique measure: Percentage % of patients with marginal staining sex: ALL minimumAge: 20 Years maximumAge: 35 Years stdAges: ADULT facility: Ali Elkaffas city: Al Kharj country: Saudi Arabia lat: 24.15541 lon: 47.33457 hasResults: False
nctId: NCT06377410 id: FF-2023-433 briefTitle: Efficacy & Safety of Dry Powder Ivy Extract (Syrup Prospan) Versus NAC Among COPD Patients acronym: SyProNAC overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2026-11-30 date: 2026-11-30 date: 2024-04-22 date: 2024-04-22 name: National University of Malaysia class: OTHER briefSummary: As the third global leading cause of death, Chronic Obstructive Pulmonary Disease (COPD) affects more than 300 million people worldwide. These patients suffer from 0.5-3.5 exacerbations per year on average. Each exacerbations dampened their health status as well as quality of life, not to mention a great burden to our healthcare system. Those partially treated or prolonged exacerbations would subsequently lead to unfavorable disease progression. Hence a holistic approach in managing each exacerbations is very crucial.
Mucolytics work by reducing sputum viscosity hence improved its expectoration. N-acetylcysteine (NAC) is a mucolytic with antioxidant and anti-inflammatory properties, commonly used in practice among COPD patients. Meanwhile, Syrup Prospan is ivy leaf preparations, obtained as extracts from leaves of the plant Hedera helix L. It is widely used over-the-counter cough remedy containing saponins which are believed to have expectorant properties. Studies show evidence of antispasmodic, bonchodilating, anti-inflammatory and antitussive properties and its usage is authorised by the European Medicines Agency . conditions: Chronic Obstructive Pulmonary Disease studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 100 type: ESTIMATED name: Syrup Prospan name: N-Acetylcysteine measure: To assess cough symptoms and its impact on daily activities using Cough and Sputum Assessment Questionnaire (CASA-Q); scores for each domain range from 0 to 100, with higher scores indicating fewer/less severe symptoms and less impact. measure: to determine change of Quality of Life using McGill COPD Quality of Life Questionnaire, scores ranged from 0 to 100, with higher scores indicating a better quality of life. measure: to determine change of Forced Expiratory Volume at 1second (FEV1); in litres/minute using spirometry measure: to determine change of Forced Vital Capacity in litres/minute using spirometry measure: to determine adverse effects of Syrup Prospan (in %) measure: to determine adverse effects of N-Acetylcysteine (in %) measure: To assess satisfaction of treatment using the 5 point Likert Scale (1- Not Satisfied, 5 - Most Satisfied) sex: ALL minimumAge: 40 Years stdAges: ADULT stdAges: OLDER_ADULT facility: National University of Malaysia city: Cheras state: Kuala Lumpur zip: 56000 country: Malaysia name: Mohamed Faisal Abdul Hamid, MBBS (IIUM) role: CONTACT phone: 0391455555 email: faisal.hamid@ppukm.ukm.edu.my lat: 3.05 lon: 101.76667 typeAbbrev: Prot_SAP_ICF hasProtocol: True hasSap: True hasIcf: True label: Study Protocol, Statistical Analysis Plan, and Informed Consent Form date: 2024-02-01 uploadDate: 2024-04-08T19:34 filename: Prot_SAP_ICF_000.pdf size: 1474657 hasResults: False
nctId: NCT06377397 id: IIRPIG-2023-0000070 briefTitle: Selective Antibiotics When Symptoms Develop Versus Universal Antibiotics for Preterm Neonates acronym: SAUNA overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2027-04-15 date: 2028-04-14 date: 2024-04-22 date: 2024-04-22 name: Indian Council of Medical Research class: OTHER_GOV name: Lady Hardinge Medical College name: King George's Medical University name: Indira Gandhi Institute of Child Health name: Institute of Obstetrics and Gynecology name: Government Medical College, Chandigarh name: Pandit Bhagwat Dayal Sharma, PGIMS, Rohtak name: Government Medical College, Aurangabad name: King Edward Memorial Hospital, Mumbai briefSummary: Preterm infants are born at less than 37 weeks of pregnancy. Sometimes a break or tear in the fluid filled bag that surrounds and protects the infant during pregnancy leads to an untimely birth. This state puts the infant at risk of serious condition called sepsis. Sepsis is a condition in which body responds inappropriately to an infection. Sepsis may progress to septic shock which can result in the loss of life. Doctors give antibiotics to treat sepsis.
3. To find out whether infants receiving selective antibiotics (as above) compared to those receiving antibiotics from birth (as above) are significantly different with respect to a wide range of secondary outcomes (listed under "Outcomes"). conditions: Sepsis conditions: PROM, Preterm (Pregnancy) conditions: Early-Onset Neonatal Sepsis conditions: Preterm Premature Rupture of Membrane conditions: Preterm Birth studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Neonates will be randomized to 1 of the following groups:
nctId: NCT06377384 id: DHP-33-FLIGHT briefTitle: FLIGHT Study for Childhood Chronic Illness overallStatus: RECRUITING date: 2022-04-20 date: 2025-09 date: 2025-09 date: 2024-04-22 date: 2024-04-23 name: Documenting Hope Project class: OTHER briefSummary: The FLIGHT study is an open-label, single-arm, pilot and feasibility study of a personalized and multimodality intervention focusing upon modifiable lifestyle factors, environmental modifications, and transdisciplinary clinical care for children with chronic illness. A mixed methods outcomes evaluation will be performed. The primary goal of this study is to evaluate the most feasible and promising strategies to inform a more streamlined and scalable intervention in the future. Up to 14 participants may be enrolled, but fewer are expected to achieve the primary goal of the study. conditions: Chronic Illnesses, Multiple studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 14 type: ESTIMATED name: FLIGHT Intervention measure: Total Load Index (TLI) measure: Child Health Inventory for Resilience and Prevention (CHIRP) measure: Children's Sleep Habits Questionnaire (CSHQ) measure: Vineland Adaptive Behavior Scale measure: Sensory Profile 2 measure: Quick Environmental Exposure and Sensitivity Inventory (QEESI) measure: Hayward Environmental Illness Severity Scale measure: Parenting Stress Index, 4th edition (PSI-4) measure: Beck Anxiety Inventory (BAI) sex: ALL minimumAge: 2 Years maximumAge: 15 Years stdAges: CHILD facility: Epidemic Answers status: RECRUITING city: Windsor state: Connecticut zip: 06095 country: United States name: Study Coordinator role: CONTACT phone: 833-935-5543 email: info@epidemicanswers.org lat: 41.8526 lon: -72.6437 hasResults: False
nctId: NCT06377371 id: 23-03025815 briefTitle: Feasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATE overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-01 date: 2025-01 date: 2024-04-22 date: 2024-04-22 name: Weill Medical College of Cornell University class: OTHER name: Curium US LLC briefSummary: The study team hypothesizes that it is feasible to intraoperatively detect tumor following \[CU64\]DOTATATE injection using the gamma probe device. conditions: Meningioma studyType: INTERVENTIONAL phases: PHASE4 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: Brain Imaging with [Cu64]DOTATATE name: Radio-guided Surgery With Neoprobe Utilization measure: Preoperative [Cu64]DOTATATE PET SUV measure: 1st Post-operative [Cu64]DOTATATE PET SUV measure: 2nd Post-operative [Cu64]DOTATATE PET SUV measure: MRI Size Measurements measure: GTR vs STR Assessment measure: MRI Progression Assessment measure: Target Lesion Neoprobe Count measure: Subtotal Neoprobe Count measure: Reference Background Neoprobe Count measure: SSTR2 expression measure: WHO grade measure: Ki67 Proliferation Index measure: ER/PR expression sex: ALL minimumAge: 18 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT facility: New York-Presbyterian/Weill Cornell Medical Center city: New York state: New York zip: 10021 country: United States lat: 40.71427 lon: -74.00597 hasResults: False
nctId: NCT06377358 id: CEEAH CA31 briefTitle: Study of Lipolysis of Visceral Reserve Fat Using Tecar Therapy. overallStatus: COMPLETED date: 2022-05-09 date: 2022-07-25 date: 2023-06-22 date: 2024-04-22 date: 2024-04-22 name: CAPENERGY MEDICAL, SL class: INDUSTRY name: University of Malaga name: Alfonso X El Sabio University briefSummary: The Scope of this study is to assess the visceral and subcutaneous fat loss in patients having Tecar (Radiofrequency) Therapy and its effects on other anthropometric variables, adipokines and inflammation.
20 obese patients will be treated with Tecar Therapy (Radiofrequency). Each patient will have 4 active, automatic plates placed on the abdomen (200 cm2 per plate), two on the right side of the midline and two on the left side. Energy will be applied for 50 minutes, controlling the temperature. Subsequently, 15 minutes of Capacitive and Resistive manual electrodes will be applied to the abdomen, simultaneously, 20 minutes of Lymphatic Drainage placing one active plate in the foot and the other in the lumbo-dorsal area. Patients will be informed that they will only feel comfortable warmth. Five sessions will be applied from Monday to Friday resting Saturday and Sunday, for 2 weeks. Total 10 sessions.
Results will be analyzed using the SPSS statistics package. A Kolmogorov-Smirnov test will be applied, if the data behaves normally, parametric tests will be applied. If not, non-parametric tests will be performed. The differences between proportions will be analyzed using Fischer's exact test. The differences between the medians will be assessed using the Student's t-test for paired samples and independent samples. conditions: Obesity, Visceral conditions: Obesity; Endocrine studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Tecar Theraty was applied to 20 obese patients in order to assess the effect on the body fat loss, serum adipocytokines and imflammation. It was an interventional study in one group of patients. No controls. No masking. primaryPurpose: TREATMENT masking: NONE count: 20 type: ACTUAL name: Tecar Therapy measure: Visceral fat loss (cm3) measure: Visceral fat loss (g) measure: Subcutaneous fat loss (cm3) measure: Subcutaneous fat loss (g) measure: Tumor Necrosis Factor alfa measure: Interleukin 6 levels measure: C reactive Protein levels measure: Leptin levels measure: Adiponectin levels measure: Resistin levels measure: Total cholesterol changes measure: Total triglycerides changes measure: LDL Cholesterol changes measure: HDL Cholesterol changes measure: Glucose measure: Body Mass Index loss measure: Waist to Hip Index loss measure: Skinfold Thickness (cm) sex: ALL minimumAge: 20 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Inneo Terapia Despi city: Barcelona country: Spain lat: 41.38879 lon: 2.15899 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2022-02-01 uploadDate: 2024-03-21T05:39 filename: Prot_SAP_000.pdf size: 597014 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2022-02-01 uploadDate: 2024-04-11T07:17 filename: ICF_001.pdf size: 543945 hasResults: False
nctId: NCT06377345 id: 202312-00011 briefTitle: Remote Patient Monitoring Solution for Chronic Respiratory Disease Management overallStatus: NOT_YET_RECRUITING date: 2024-04-20 date: 2024-12-31 date: 2025-03-30 date: 2024-04-22 date: 2024-04-22 name: SingHealth Polyclinics class: OTHER briefSummary: Aim: To evaluate the use of AeviceMD Monitoring System (AeviceMD) asthma in reducing acute exacerbation.
Methodology: Using a randomized controlled trial design, this project aims evaluate the effectiveness of AeviceMD in improving patients' outcomes in terms of reducing exacerbation, healthcare utilization, improving quality of life, self-efficacy, and cost effectiveness. Paediatric patients above age 7 and adults will be recruited. The data follow-up period is 3 months. It will also evaluate the usability of the device from both patients' and clinicians' perspective. 180 patients (124 adults, 56 pediatrics) and 120 clinicians will be recruited.
Potential benefits and risk: AeviceMD allows for remote monitoring and tracking of patients' lung sounds, which could be used by patients to monitor their lung condition and prevent an episode of exacerbation or worsening exacerbations culminating in an admission which who further utilize already limited healthcare resources. An exacerbation is an episode of severe shortness of breath, cough, and chest tightening which warrants a visit to a healthcare institution. Through self-monitoring, patients can be empowered to self-manage their asthma, with aid of the asthma action plan which is given to all patients with asthma. AeviceMD can also help provide clinicians with patients' objective lung data. In the primary care setting, care is also fragmented as patients are often followed-up by a different doctor or healthcare providers. Clinicians have no objective data to track patients, and is dependent on patients' self-report and possible recall bias. There is no expected risk with the use of the device. conditions: Asthma conditions: Asthma Attack conditions: Asthma in Children conditions: Asthma Acute conditions: Asthma Chronic studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: A two-group randomized controlled trial (RCT) design will be used. The control group will receive the usual care, and the intervention group will receive the Aevice device on top of usual care. Outcomes will be measured at baseline, week 4, and week 12. This is to evaluate the long-term impacts of the Aevice device. Clinicians who have interacted with participants using Aevice will also be invited to participate in an interview and clinician perception survey. A convenience sampling will be used for the recruitment of clinicians. primaryPurpose: PREVENTION masking: SINGLE maskingDescription: The outcomes assessor will not be aware of the participants' group whoMasked: OUTCOMES_ASSESSOR count: 180 type: ESTIMATED name: AeviceMD device name: Standard care measure: Rescue therapy measure: Dose of oral Prednisolone use measure: Visit to hospital emergency department measure: Hospitalisation measure: Euro Quality of Life 5 dimensions (EQ5D) measure: Asthma quality of life questionnaire (AQLQ) measure: Pediatric asthma quality of life questionnaire (PAQLQ) measure: Self-efficacy measure: Usability measure: Heart rate measure: Respiratory rate measure: Wheeze detection trend measure: Medication log measure: Duration of device usage measure: Payment sex: ALL minimumAge: 7 Years maximumAge: 90 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06377332 id: X23-0330 briefTitle: Biomarkers of Dementia in Chronic Sleep and Breathing Disorders acronym: ORACLE overallStatus: RECRUITING date: 2023-12-01 date: 2025-07-01 date: 2025-07-01 date: 2024-04-22 date: 2024-04-22 name: Woolcock Institute of Medical Research class: OTHER briefSummary: Chronic obstructive pulmonary disease (COPD), obstructive sleep apnoea (OSA) and overlap syndrome are associated with obstructions in breathing and disturbed sleep.